GLK-221 eye drops compared with placebo drops for keratoconus
Tests GLK-221 eye drops against placebo drops in adults with keratoconus.
Key facts
- Who runs it
- Glaukos Corporation
- Where
- Westerville, United StatesSee the site
- Trial code
- Registry title
- Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 23 Dec 2025
- Expected to end
- Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- GLK-221 Ophthalmic Solution
- Placebo Ophthalmic Solution
- Record updated
- 10 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with keratoconus, an eye condition where the clear front surface of the eye (cornea) thins and bulges. It tests GLK-221 eye drops against placebo drops.
- Age
- 18 to 55 years
- Sex
- All sexes
- Disease stage
- Keratoconus diagnosed in the study eye.
Main reasons for not taking part
- Pregnant or breastfeeding
- Planning a pregnancy
- Taking part in another trial of an experimental drug or device now, or within 30 days before screening
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Be ≥ 18 and ≤ 55 years of age
- Diagnosis of keratoconus in the study eye
Who cannot take part
- Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
- Pregnant, lactating or planning a pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Where in United States
- Westerville, OhioHospital not named in the registryContact: Study ManagerTaking people
About the trial
What the trial wants to find out
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
The 2 groups in the trial
- GLK-221 Ophthalmic SolutionTreatment being tested
GLK-221 Ophthalmic Solution administered topically twice daily to both eyes
- PlaceboPlacebo, for comparison
Placebo Ophthalmic Solution administered topically twice daily to both eyes
Treatment: Placebo Ophthalmic Solution
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
- Plain-language title
- GLK-221 eye drops compared with placebo drops for keratoconusGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07400952, who can take part
- Record updated
- 10 February 2026